Three of the five most expensive drugs used by Vizient’s clients are specialty drugs — Humira (adalimumab), Stelara (ustekinumab), and Prolia and Xgeva denosumab (denosumab) — and two neurology drugs recently broke into the top 100 medications by member spend, Tecvayli (teclistamab) and Kimmtrak (tebentafusp).
In 2022, specialty drug costs made up 51 percent of hospital pharmaceutical spend. Some factors that are forecasted to lower these costs include Humira biosimilars; the falling use of COVID-19 treatment remdesivir; and Briumvi (ublituximab), the cheapest approved drug for relapsing forms of multiple sclerosis.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.